Anthony C Vernon

List of Publications by Year
in descending order

73	2,510	218677	223800
papers	citations	26 h-index	46 g-index

86	86	86	3926
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia. Neuropsychopharmacology, 2022, 47, 687-695.	5.4	6
2	Preclinical animal models of mental illnesses to translate findings from the bench to the bedside: Molecular brain mechanisms and peripheral biomarkers associated to early life stress or immune challenges. European Neuropsychopharmacology, 2022, 58, 55-79.	0.7	22
3	Cellular and molecular signatures of in vivo imaging measures of GABAergic neurotransmission in the human brain. Communications Biology, 2022, 5, 372.	4.4	1
4	A unique cerebellar pattern of microglia activation in a mouse model of encephalopathy of prematurity. Glia, 2022, 70, 1699-1719.	4.9	7
5	Attenuated transcriptional response to pro-inflammatory cytokines in schizophrenia hiPSC-derived neural progenitor cells. Brain, Behavior, and Immunity, 2022, 105, 82-97.	4.1	7
6	Behavioral, neuroanatomical, and molecular correlates of resilience and susceptibility to maternal immune activation. Molecular Psychiatry, 2021, 26, 396-410.	7.9	80
7	Systemic Î±-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinsonâ€™s disease. Molecular Psychiatry, 2021, 26, 556-567.	7.9	24
8	Application of Airy beam light sheet microscopy to examine early neurodevelopmental structures in 3D hiPSC-derived human cortical spheroids. Molecular Autism, 2021, 12, 4.	4.9	14
9	Microglia and Psychiatric Disorders. , 2021, , 133-157.		1
10	Functional brain defects in a mouse model of a chromosomal t(1;11) translocation that disrupts DISC1 and confers increased risk of psychiatric illness. Translational Psychiatry, 2021, 11, 135.	4.8	3
11	Transvascular delivery of Î±-synuclein preformed fibrils, using the RVG9R delivery system, generates Î±-synuclein pathology in the duodenal myenteric plexus of non-transgenic rats. Molecular Psychiatry, 2021, 26, 365-365.	7.9	1
12	MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Communications, 2021, 3, fcab114.	3.3	11
13	Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	7
14	Viewpoint | European COVID-19 exit strategy for people with severe mental disorders: Too little, but not yet too late. Brain, Behavior, and Immunity, 2021, 94, 15-17.	4.1	17
15	Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behavioural Brain Research, 2021, 405, 113203.	2.2	10
16	Brain volume in chronic ketamine users â€" relationship to sub-threshold psychotic symptoms and relevance to schizophrenia. Psychopharmacology, 2021, , 1.	3.1	1
17	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
18	Sexually dimorphic neuroanatomical differences relate to ASD-relevant behavioral outcomes in a maternal autoantibody mouse model. Molecular Psychiatry, 2021, 26, 7530-7537.	7.9	12

#	Article	IF	Citations
19	Editorial: Cardiovascular and Physical Health in Severe Mental Illness. Frontiers in Psychiatry, 2021, 12, 760250.	2.6	1
20	Maternal immune activation primes deficiencies in adult hippocampal neurogenesis. Brain, Behavior, and Immunity, 2021, 97, 410-422.	4.1	20
21	Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?. Schizophrenia Bulletin, 2020, 46, 484-495.	4.3	17
22	Corrigendum to: Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?. Schizophrenia Bulletin, 2020, , .	4.3	0
23	Neuroanatomical and Microglial Alterations in the Striatum of Levodopa-Treated, Dyskinetic Hemi-Parkinsonian Rats. Frontiers in Neuroscience, 2020, 14, 567222.	2.8	10
24	Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System. CNS Drugs, 2020, 34, 1229-1251.	5.9	26
25	Emerging Developments in Human Induced Pluripotent Stem Cell-Derived Microglia: Implications for Modelling Psychiatric Disorders With a Neurodevelopmental Origin. Frontiers in Psychiatry, 2020, 11, 789.	2.6	14
26	Interferon-Î³ signaling in human iPSCâ€“derived neurons recapitulates neurodevelopmental disorder phenotypes. Science Advances, 2020, 6, eaay9506.	10.3	56
27	Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain. European Neuropsychopharmacology, 2020, 41, 106-117.	0.7	12
28	Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-NaÃ¯ve Schizophrenia Patients. Frontiers in Neuroscience, 2020, 14, 484.	2.8	15
29	Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk. Frontiers in Psychiatry, 2020, 11, 72.	2.6	138
30	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11, 246.	12.8	148
31	Planar Airy beam light-sheet for two-photon microscopy. Biomedical Optics Express, 2020, 11, 3927.	2.9	31
32	From early adversities to immune activation in psychiatric disorders: the role of the sympathetic nervous system. Clinical and Experimental Immunology, 2019, 197, 319-328.	2.6	34
33	Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory. Journal of Psychopharmacology, 2019, 33, 1274-1287.	4.0	12
34	The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells. Biological Psychiatry, 2019, 86, 120-130.	1.3	42
35	Mapping the impact of exposure to maternal immune activation on juvenile Wistar rat brain macro- and microstructure during early post-natal development. Brain and Neuroscience Advances, 2019, 3, 239821281988308.	3.4	3
36	Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects. Brain, Behavior, and Immunity, 2019, 75, 48-59.	4.1	66

#	Article	IF	Citations
37	An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers. Human Brain Mapping, 2018, 39, 319-331.	3.6	27
38	Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. Neuroscience and Biobehavioral Reviews, 2018, 85, 146-159.	6.1	63
39	Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology, 2018, 95, 28-33.	2.7	12
40	Brain microglia in psychiatric disorders. Lancet Psychiatry,the, 2017, 4, 563-572.	7.4	208
41	Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study. Brain, Behavior, and Immunity, 2017, 63, 50-59.	4.1	64
42	287. Neuroadaptations to Chronic Ketamine Exposure: A Parallel Human and Mouse MRI Imaging Study. Biological Psychiatry, 2017, 81, S118.	1.3	1
43	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neuroscience and Biobehavioral Reviews, 2017, 76, 317-335.	6.1	31
44	Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0172394.	2.5	8
45	Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0180733.	2.5	9
46	Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss. Psychological Medicine, 2016, 46, 3081-3093.	4.5	14
47	Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system. Neuroscience, 2016, 334, 166-179.	2.3	9
48	Simultaneous effects on parvalbumin-positive interneuron and dopaminergic system development in a transgenic rat model for sporadic schizophrenia. Scientific Reports, 2016, 6, 34946.	3.3	27
49	Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model. PeerJ, 2016, 4, e2632.	2.0	53
50	Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology, 2015, 25, 2098-2107.	0.7	77
51	Neurorestoration induced by the <scp>HDAC</scp> inhibitor sodium valproate in the lactacystin model of <scp>P</scp>arkinson's is associated with histone acetylation and upâ€regulation of neurotrophic factors. British Journal of Pharmacology, 2015, 172, 4200-4215.	5.4	46
52	Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinicâ€“polycytidylic acid in utero. European Neuropsychopharmacology, 2015, 25, 2210-2220.	0.7	32
53	The brain's code and its canonical computational motifs. From sensory cortex to the default mode network: A multi-scale model of brain function in health and disease. Neuroscience and Biobehavioral Reviews, 2015, 55, 211-222.	6.1	48
54	Brain Morphometry and the Neurobiology of Levodopa-Induced Dyskinesias: Current Knowledge and Future Potential for Translational Pre-Clinical Neuroimaging Studies. Frontiers in Neurology, 2014, 5, 95.	2.4	23

#	Article	IF	Citations
55	Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugsâ€"Linking Magnetic Resonance Imaging Findings to Cellular Pathology. Biological Psychiatry, 2014, 75, 982-990.	1.3	85
56	Registration of challenging pre-clinical brain images. Journal of Neuroscience Methods, 2013, 216, 62-77.	2.5	16
57	Effects of Lithium on Magnetic Resonance Imaging Signal Might Not Preclude Increases in Brain Volume After Chronic Lithium Treatment. Biological Psychiatry, 2013, 74, e39-e40.	1.3	6
58	Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Translational Psychiatry, 2013, 3, e208-e208.	4.8	24
59	Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation. Biological Psychiatry, 2012, 71, 855-863.	1.3	113
60	Reply to: Lithium and the Expanding Brain. Biological Psychiatry, 2012, 72, e19.	1.3	0
61	Do levodopa treatments modify the morphology of the parkinsonian brain?. Movement Disorders, 2012, 27, 166-167.	3.9	16
62	Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation. Biological Psychiatry, 2011, 69, 936-944.	1.3	166
63	Selective activation of metabotropic glutamate receptor 7 induces inhibition of cellular proliferation and promotes astrocyte differentiation of ventral mesencephalon human neural stem/progenitor cells. Neurochemistry International, 2011, 59, 421-431.	3.8	12
64	Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's Disease. PLoS ONE, 2011, 6, e17269.	2.5	44
65	Non-invasive MR Imaging of Neurodegeneration in a Rodent Model of Parkinsonâ€™s Disease. Methods in Molecular Biology, 2011, 711, 487-510.	0.9	1
66	Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neuroscience, 2010, 11, 1.	1.9	137
67	Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of Î±-synuclein neuropathology required and feasible?. Brain Research Reviews, 2010, 65, 28-55.	9.0	39
68	Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease. Parkinson's Disease, 2010, 2010, 1-12.	1.1	19
69	Mice with Reduced Vesicular Monoamine Storage Content Display Nonmotor Features of Parkinson's Disease: Table 1.. Journal of Neuroscience, 2009, 29, 12842-12844.	3.6	6
70	Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. NeuroReport, 2008, 19, 475-478.	1.2	21
71	Selective Activation of Group III Metabotropic Glutamate Receptors by l-(+)-2-Amino-4-phosphonobutryic Acid Protects the Nigrostriatal System against 6-Hydroxydopamine Toxicity in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 397-409.	2.5	32
72	Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6â€hydroxydopamine toxicity in vivo. Journal of Neurochemistry, 2007, 103, 1075-1091.	3.9	49

#	Article	IF	Citations
73	Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. European Journal of Neuroscience, 2005, 22, 1799-1806.	2.6	71